ARNA Genomics

Executive Summary

ARNA Genomics is a private biotechnology company focused on developing multiomics liquid biopsy technologies for early cancer detection. Based in San Diego, the company is advancing its lead assay, ARNA Breast, designed for early-stage breast cancer diagnosis through a simple blood test. Leveraging decades of expertise in molecular biology and genetics, ARNA aims to improve survival rates by detecting cancer at earlier, more treatable stages. While the company has not disclosed recent funding rounds or valuation, its long history since 1998 suggests deep scientific roots. The liquid biopsy market is rapidly expanding, and ARNA's multiomics approach could differentiate it from competitors if clinical validation succeeds. However, the company remains in development stage with no commercial products yet, posing execution risk.

Upcoming Catalysts (preview)

• Q4 2026Clinical data readout from ARNA Breast trial60% success
• Q2 2027Strategic partnership or licensing deal40% success
• Q3 2026FDA breakthrough device designation for ARNA Breast50% success